Literature DB >> 22203610

Effects of chemotherapeutics on organotypic corticostriatal slice cultures identified by a panel of fluorescent and immunohistochemical markers.

Annette Nørregaard1, Stine Skov Jensen, Jesper Kolenda, Charlotte Aaberg-Jessen, Karina Garnier Christensen, Poul Henning Jensen, Henrik Daa Schrøder, Bjarne Winther Kristensen.   

Abstract

Effects of chemotherapeutics on glioma cell lines and spheroids are usually investigated without evaluating the effects of chemotherapeutics on normal brain tissue. To perform such investigations, the aim of this study was to establish a panel of markers for detection of general cell death and more specific neuronal and glial degeneration induced by chemotherapeutics in organotypic rat corticostriatal slice cultures. The slice cultures were exposed to the alkylating agents temozolomide (TMZ) and nimustine (ACNU), the tyrosine kinase inhibitor imatinib mesylate (IM) and the microtubule-destabilizing agent vincristine (VCR). Densitometric measurements of uptake of the fluorescent dye propidium iodide (PI) were used for quantifying cellular degeneration. Moreover, paraffin sections were hematoxylin eosine stained and immunostained for the neuronal marker microtubule-associated protein 2 (MAP2), the astroglial marker glial fibrillary acidic protein (GFAP), and the oligodendroglial marker p25α. The results showed that the supposed clinically relevant drug concentrations were non-toxic. However, a time dependent increase in PI uptake was observed for high drug concentrations, except for TMZ, where no toxicity was observed. Corresponding immunostaining showed loss of MAP2 and increased expression of GFAP and p25α for cultures exposed to 1,000 nM VCR. Cultures exposed to high concentrations of ACNU and IM disintegrated, leaving no tissue for histology. In conclusion, corticostriatal slice cultures and the established panel of markers represent an excellent tool for detecting toxicity induced by chemotherapeutics. Toxicity was not detected at clinical concentrations, but high concentrations with toxic effects were identified suggesting that some of the earlier identified anti-cancer effects are general cytotoxic effects and not specific anti-cancer effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22203610     DOI: 10.1007/s12640-011-9300-9

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  89 in total

1.  Mechanism of inhibition of cell proliferation by Vinca alkaloids.

Authors:  M A Jordan; D Thrower; L Wilson
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

2.  P25alpha/Tubulin polymerization promoting protein expression by myelinating oligodendrocytes of the developing rat brain.

Authors:  Tina Skjoerringe; Ditte M S Lundvig; Poul H Jensen; Torben Moos
Journal:  J Neurochem       Date:  2006-07-31       Impact factor: 5.372

3.  Excitotoxic effects of non-NMDA receptor agonists in organotypic corticostriatal slice cultures.

Authors:  B W Kristensen; J Noraberg; B Jakobsen; J B Gramsbergen; B Ebert; J Zimmer
Journal:  Brain Res       Date:  1999-09-11       Impact factor: 3.252

4.  Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).

Authors:  Susanne Oertel; Robert Krempien; Katja Lindel; Angelika Zabel; Stephanie Milker-Zabel; Marc Bischof; Kenneth E Lipson; Peter Peschke; Jürgen Debus; Amir Abdollahi; Peter E Huber
Journal:  Strahlenther Onkol       Date:  2006-07       Impact factor: 3.621

5.  Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.

Authors:  Ji Tae Kim; Jong-Soo Kim; Kwang Won Ko; Doo-Sik Kong; Chang-Mo Kang; Mi Hyun Kim; Myung Jin Son; Hyun Seok Song; Hyung-Jin Shin; Dong-Sup Lee; Whan Eoh; Do-Hyun Nam
Journal:  Oncol Rep       Date:  2006-07       Impact factor: 3.906

6.  Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.

Authors:  Tiziana Servidei; Anna Riccardi; Maurizio Sanguinetti; Carlo Dominici; Riccardo Riccardi
Journal:  J Cell Physiol       Date:  2006-07       Impact factor: 6.384

7.  Penetration of intra-arterially administered vincristine in experimental brain tumor.

Authors:  Frances M Boyle; Susan L Eller; Stuart A Grossman
Journal:  Neuro Oncol       Date:  2004-10       Impact factor: 12.300

8.  Low concentrations of STI571 in the cerebrospinal fluid: a case report.

Authors:  Andreas L Petzer; Eberhard Gunsilius; Michael Hayes; Guenther Stockhammer; Hans C H Duba; Folker Schneller; Kurt Grünewald; Werner Poewe; Guenther Gastl
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998

9.  Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.

Authors:  Takashi Shingu; Kazuo Yamada; Nobumasa Hara; Kouzo Moritake; Harumi Osago; Masaharu Terashima; Takeshi Uemura; Toshiki Yamasaki; Mikako Tsuchiya
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

10.  Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.

Authors:  Heike Pfeifer; Barbara Wassmann; Wolf-Karsten Hofmann; Martina Komor; Urban Scheuring; Patrick Brück; Anja Binckebanck; Eberhard Schleyer; Nicola Gökbuget; Thomas Wolff; Michael Lübbert; Lothar Leimer; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

View more
  7 in total

1.  Interrogation of kinase genetic interactions provides a global view of PAK1-mediated signal transduction pathways.

Authors:  Jae-Hong Kim; Yeojin Seo; Myungjin Jo; Hyejin Jeon; Young-Seop Kim; Eun-Jung Kim; Donggun Seo; Won-Ha Lee; Sang Ryong Kim; Nozomu Yachie; Quan Zhong; Marc Vidal; Frederick P Roth; Kyoungho Suk
Journal:  J Biol Chem       Date:  2020-10-15       Impact factor: 5.157

2.  Mitochondrial-associated impairments of temozolomide on neural stem/progenitor cells and hippocampal neurons.

Authors:  Naomi Lomeli; Kaijun Di; Diana C Pearre; Tzu-Feng Chung; Daniela A Bota
Journal:  Mitochondrion       Date:  2020-02-08       Impact factor: 4.160

3.  B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.

Authors:  Wynand P Roos; Steve Quiros; Andrea Krumm; Stephanie Merz; Olivier Jérôme Switzeny; Markus Christmann; Carmen Loquai; Bernd Kaina
Journal:  Oncotarget       Date:  2014-12-30

4.  Antitumor effect of fibrin glue containing temozolomide against malignant glioma.

Authors:  Shigeo Anai; Takuichiro Hide; Tatsuya Takezaki; Jun-ichiro Kuroda; Naoki Shinojima; Keishi Makino; Hideo Nakamura; Shigetoshi Yano; Jun-ichi Kuratsu
Journal:  Cancer Sci       Date:  2014-04-19       Impact factor: 6.716

5.  Chemotherapeutic xCT inhibitors sorafenib and erastin unraveled with the synaptic optogenetic function analysis tool.

Authors:  Marc Dahlmanns; Eduard Yakubov; Daishi Chen; Tina Sehm; Manfred Rauh; Nicolai Savaskan; Jana Katharina Wrosch
Journal:  Cell Death Discov       Date:  2017-06-19

6.  Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo.

Authors:  Stine S Jensen; Stine A Petterson; Bo Halle; Charlotte Aaberg-Jessen; Bjarne W Kristensen
Journal:  BMC Cancer       Date:  2017-03-07       Impact factor: 4.430

7.  Establishment and Characterization of a Tumor Stem Cell-Based Glioblastoma Invasion Model.

Authors:  Stine Skov Jensen; Morten Meyer; Stine Asferg Petterson; Bo Halle; Ann Mari Rosager; Charlotte Aaberg-Jessen; Mads Thomassen; Mark Burton; Torben A Kruse; Bjarne Winther Kristensen
Journal:  PLoS One       Date:  2016-07-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.